The Trump administration, via the US Department of Health and Human Services, eases access to certain unproven peptide drugs by allowing compounding pharmacies to dispense specific peptide combinations. Multiple outlets report the policy targets a small set of injectable peptides promoted in the wellness and performance industries, and it is tied to guidance published by HHS.
The change reduces FDA enforcement action for these products while the agency continues working toward a more formal rule change. Scientific American and other coverage describe the update as affecting six “popular” peptides and notes that certain combinations can be dispensed by eligible pharmacies. NBC News describes it as a temporary step, with HHS providing compounding pharmacies short-term authorization.
Several outlets also report that FDA scientific staff opposed the move. The Guardian and other reports say most FDA scientific personnel had limited input into the policy’s drafting and pushed back over concerns that it could weaken the agency’s approach to unproven drugs. Some stories highlight specific peptides named in connection with wellness use, while others focus more on the internal process and dispute between agencies.
